Wacker Biotech and Actym Therapeutics Partner for Treatment of Solid Tumors
Actym Therapeutics, a biotechnology company focusing on the development and discovery of the novel therapies and Wacker Biotech has announced that, they have signed a contract for the process of manufacturing of the ACTM-838, a leading clinical candidate of Actym for the purpose of treating the solid tumors. Under the terms of the partnership or […]
Continue Reading